Aprea Therapeutics (APRE) Analyst & Key Data

Analyst Consensus

Buy8 analysts

Buy

Updated Sep 12, 2026

Total Analysts8

Buy

4

Hold

2

Sell

2

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score5.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$0.77

DCF Value+175.96%

$2.14

Potential upside vs current price

Current Stock Price

$0.77

DCF Value+175.96%

$2.14

Potential upside vs current price

Analyst Consensus

Buy8 analysts

Buy

Updated Sep 12, 2026

Total Analysts8

Buy

4

Hold

2

Sell

2

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score5.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$0.77

DCF Value+175.96%

$2.14

Potential upside vs current price

Current Stock Price

$0.77

DCF Value+175.96%

$2.14

Potential upside vs current price

Aprea Therapeutics, Inc.